F-star Therapeutics, Inc.
FSTX · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $21,167 | $11,256 | $28,321 | $0 |
| % Growth | 88.1% | -60.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $21,167 | $11,256 | $28,321 | $0 |
| % Margin | 100% | 100% | 100% | – |
| R&D Expenses | $28,750 | $14,128 | $31,386 | $19,751 |
| G&A Expenses | $23,131 | $19,513 | $15,280 | $8,719 |
| SG&A Expenses | $23,131 | $19,513 | $15,280 | $8,719 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $51,881 | $33,641 | $46,666 | $28,470 |
| Operating Income | -$30,714 | -$22,385 | -$22,497 | -$28,470 |
| % Margin | -145.1% | -198.9% | -79.4% | – |
| Other Income/Exp. Net | -$941 | -$3,235 | -$1,600 | $5,616 |
| Pre-Tax Income | -$31,655 | -$25,620 | -$23,750 | -$22,854 |
| Tax Expense | -$372 | -$1 | -$737 | $0 |
| Net Income | -$31,283 | -$25,619 | -$23,013 | -$22,854 |
| % Margin | -147.8% | -227.6% | -81.3% | – |
| EPS | -1.88 | -2.82 | -2.54 | -1.6 |
| % Growth | 33.3% | -11% | -58.7% | – |
| EPS Diluted | -1.88 | -2.82 | -2.54 | -1.6 |
| Weighted Avg Shares Out | 16,647 | 9,085 | 9,070 | 14,619 |
| Weighted Avg Shares Out Dil | 16,647 | 9,085 | 9,070 | 14,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $999 |
| Interest Expense | $844 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,293 | $1,144 | $9,148 | $288 |
| EBITDA | -$29,421 | -$21,241 | -$13,349 | -$28,470 |
| % Margin | -139% | -188.7% | -47.1% | – |